{"id":"mk0954-duration-of-treatment-16-weeks","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3930496","moleculeType":"Small molecule","molecularWeight":"477.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing NK1 receptors, MK0954 inhibits the binding of substance P, a neuropeptide involved in pain transmission and emetic pathways. This mechanism is thought to provide analgesic and antiemetic effects. The drug crosses the blood-brain barrier to act on central NK1 receptors.","oneSentence":"MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:47.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain conditions (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00541684","phase":"PHASE3","title":"Health Assessment Study (0954-946)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-11","conditions":"Hypertension","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0954, /Duration of Treatment : 16 Weeks","genericName":"MK0954, /Duration of Treatment : 16 Weeks","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chronic pain conditions (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}